Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1673-1678

  Ahmad, Imran ^a   Labbé, Annie Claude ^b   Chagnon, Miguel ^a   Busque, Lambert ^a   Cohen, Sandra ^a   Kiss, Thomas ^a   Lachance, Silvy ^a   Roy, Denis Claude ^a   Sauvageau, Guy ^a   Roy, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Eosinophilia; Graft versus host disease; Hematopoietic stem cell transplantation; Nonmyeloablative

Indexed keywords

DACLIZUMAB; IMATINIB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; ENTEROPATHY; EOSINOPHIL COUNT; EOSINOPHILIA; EYE DISEASE; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; INCIDENCE; LIVER DISEASE; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH DISEASE; ORGAN DONOR; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; PROPHYLAXIS; RELAPSE; SIBLING; SKIN DISEASE; THROMBOCYTOPENIA;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; EOSINOPHILIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80054864472     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.04.012     Document Type: Article

References (22)

1. Pavletic S.Z., Vogelsang G.B. Chronic graft-versus-host disease: clinical manifestations and therapy. Thomas' Hematopoietic Cell Transplantation 2009, 1304-1324. Wiley-Blackwell, New York. 4th ed. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
2. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-966.
3. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
4. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007, 13:1207-1215.
5. Cho B.K., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.
6. Arora M., Nagaraj S., Witte J., et al. New classification of chronic graft versus host disease: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
7. Akpek G., Lee S.J., Flowers M.E., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003, 102:802-809.
8. Pavletic S.Z., Smith L.M., Bishop M.R., et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 2005, 78:265-274.
9. Sato T., Kobayashi R., Nakajima M., et al. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome. Bone Marrow Transplant 2005, 36:985-991.
10. Aisa Y., Mori T., Nakazato T., et al. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. Transplant Int 2007, 20:761-770.
11. Imahashi N., Miyamura K., Seto A., et al. Eosinophilia predicts better overall survival after acute graft-versus-host-disease. Bone Marrow Transplant 2010, 45:371-377.
12. Kim D.H., Popradi G., Xu W., et al. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:471-482.
13. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
14. Subramaniam D.S., Fowler D.H., Pavletic S.Z. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia 2007, 21:853-859.
15. Sabry W., Le Blanc R., Labbé A.C., et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009, 15:919-929.
16. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
17. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
18. Bolaños-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005, 23:2661-2668.
19. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
20. Jacobsohn D.A., Chen A.R., Zahurak M., et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007, 25:4255-4261.
21. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114:719-722.
22. Boivin G., Bélanger R., Delage R., et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000, 38:4356-4360.